Story thread · 16 reports / 12 sources
Replimune in the spotlight: Earnings loom days after FDA approval
investing.com · 2d
How the coverage leans
Across 12 sources · syndicated copies counted once
First report: FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma — fda.gov, 5d
The coverage
- Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA
medcitynews.com · 3d
- Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
finance.yahoo.com · 4d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.